GAPDH and Alzheimer disease: These data suggest that GAPDH can be a target for AD therapy, which was proved in our work: the use of the GAPDH binder, a hydrocortisone derivative RX624, in the 5xFAD transgenic mice model led to a significant slowdown in the progress of memory impairment and the formation of amyloid plaques.